S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.25 (-1.67%)
MSFT   398.79 (-1.36%)
META   482.93 (-3.76%)
GOOGL   153.41 (-1.67%)
AMZN   174.62 (-2.57%)
TSLA   148.76 (-0.78%)
NVDA   805.31 (-4.89%)
AMD   147.96 (-4.59%)
NIO   3.81 (-4.75%)
BABA   68.52 (-0.52%)
T   16.34 (+0.06%)
F   12.09 (+0.25%)
MU   106.97 (-4.43%)
GE   148.61 (-2.83%)
CGC   8.01 (+2.30%)
DIS   111.29 (-1.01%)
AMC   3.18 (+8.90%)
PFE   25.80 (+1.61%)
PYPL   61.77 (-0.53%)
XOM   119.89 (+1.16%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.25 (-1.67%)
MSFT   398.79 (-1.36%)
META   482.93 (-3.76%)
GOOGL   153.41 (-1.67%)
AMZN   174.62 (-2.57%)
TSLA   148.76 (-0.78%)
NVDA   805.31 (-4.89%)
AMD   147.96 (-4.59%)
NIO   3.81 (-4.75%)
BABA   68.52 (-0.52%)
T   16.34 (+0.06%)
F   12.09 (+0.25%)
MU   106.97 (-4.43%)
GE   148.61 (-2.83%)
CGC   8.01 (+2.30%)
DIS   111.29 (-1.01%)
AMC   3.18 (+8.90%)
PFE   25.80 (+1.61%)
PYPL   61.77 (-0.53%)
XOM   119.89 (+1.16%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.25 (-1.67%)
MSFT   398.79 (-1.36%)
META   482.93 (-3.76%)
GOOGL   153.41 (-1.67%)
AMZN   174.62 (-2.57%)
TSLA   148.76 (-0.78%)
NVDA   805.31 (-4.89%)
AMD   147.96 (-4.59%)
NIO   3.81 (-4.75%)
BABA   68.52 (-0.52%)
T   16.34 (+0.06%)
F   12.09 (+0.25%)
MU   106.97 (-4.43%)
GE   148.61 (-2.83%)
CGC   8.01 (+2.30%)
DIS   111.29 (-1.01%)
AMC   3.18 (+8.90%)
PFE   25.80 (+1.61%)
PYPL   61.77 (-0.53%)
XOM   119.89 (+1.16%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   415.91 (-1.77%)
AAPL   164.25 (-1.67%)
MSFT   398.79 (-1.36%)
META   482.93 (-3.76%)
GOOGL   153.41 (-1.67%)
AMZN   174.62 (-2.57%)
TSLA   148.76 (-0.78%)
NVDA   805.31 (-4.89%)
AMD   147.96 (-4.59%)
NIO   3.81 (-4.75%)
BABA   68.52 (-0.52%)
T   16.34 (+0.06%)
F   12.09 (+0.25%)
MU   106.97 (-4.43%)
GE   148.61 (-2.83%)
CGC   8.01 (+2.30%)
DIS   111.29 (-1.01%)
AMC   3.18 (+8.90%)
PFE   25.80 (+1.61%)
PYPL   61.77 (-0.53%)
XOM   119.89 (+1.16%)
Free Trial
OTCMKTS:NBIO

Nascent Biotech (NBIO) Stock Price, News & Analysis

→ 2024's Must-Have Guide: Master Crypto Investment Today (From Darwin) (Ad)
Free NBIO Stock Alerts
$0.09
0.00 (0.00%)
(As of 04/18/2024 ET)
Compare
Today's Range
$0.09
▼
$0.09
50-Day Range
$0.09
▼
$0.18
52-Week Range
$0.03
▼
$0.28
Volume
453 shs
Average Volume
79,411 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest
NBIO stock logo

About Nascent Biotech Stock (OTCMKTS:NBIO)

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. The company has collaboration with Hypospray Pharma to develop an alternative delivery mechanism for patients who can benefit from Pritumumab. Nascent Biotech, Inc. is based in North Palm Beach, Florida.

NBIO Stock Price History

NBIO Stock News Headlines

April 16, 2024 | msn.com
Nascent Biotech prepares for pivotal Phase II research with fresh manufacturing run
April 16, 2024 | finanznachrichten.de
Nascent Biotech Inc.: Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
April 19, 2024 | DTI (Ad)
With the “Bitcoin Loophole” you can supercharge the gains by 10x or more
Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…
April 15, 2024 | americanbankingnews.com
Nascent Biotech, Inc. (OTCMKTS:NBIO) Short Interest Up 21.8% in March
April 11, 2024 | americanbankingnews.com
Nascent Biotech (OTCMKTS:NBIO) Stock Passes Below 50-Day Moving Average of $0.13
March 19, 2024 | finanznachrichten.de
Nascent Biotech Inc.: Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
March 2, 2024 | morningstar.com
Nascent Biotech Inc NBIO
February 6, 2024 | finanznachrichten.de
Nascent Biotech Inc.: Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
April 19, 2024 | DTI (Ad)
With the “Bitcoin Loophole” you can supercharge the gains by 10x or more
Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…
February 6, 2024 | finance.yahoo.com
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
January 10, 2024 | finanznachrichten.de
Nascent Biotech Inc.: Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
January 9, 2024 | finance.yahoo.com
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
December 19, 2023 | finance.yahoo.com
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
November 29, 2023 | finance.yahoo.com
Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier
November 15, 2023 | usnews.com
Isana Nascent Academy
October 26, 2023 | bizjournals.com
Chicago to showcase its biotech sector at capital summit next week
September 2, 2023 | washingtonpost.com
A tropical storm could threaten Florida next week. Here’s what we know.
August 22, 2023 | finance.yahoo.com
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer
June 7, 2023 | finanznachrichten.de
Nascent Biotech Inc.: Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
May 26, 2023 | finanznachrichten.de
Nascent Biotech Inc.: Nascent Biotech Regains Worldwide Rights for Pritumumab
May 26, 2023 | finance.yahoo.com
Nascent Biotech Regains Worldwide Rights for Pritumumab
May 9, 2023 | finanznachrichten.de
Nascent Biotech Inc.: Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
May 9, 2023 | finance.yahoo.com
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
April 18, 2023 | finanznachrichten.de
Nascent Biotech Inc.: Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
April 18, 2023 | finance.yahoo.com
Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
February 28, 2023 | finanznachrichten.de
Nascent Biotech Inc.: Nascent Announces the Completion of Its Phase1 Clinical Trials
February 28, 2023 | finance.yahoo.com
Nascent Announces the Completion of Its Phase1 Clinical Trials
See More Headlines
Receive NBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nascent Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Next Earnings (Estimated)
6/29/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:NBIO
CUSIP
N/A
CIK
1622057
Web
www.nascentbiotech.com
Phone
(612) 961-5656
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Sean Carrick (Age 56)
    President, CEO, Secretary & Director
    Comp: $252k
  • Mr. Lowell Holden (Age 81)
    CFO, Chief Accounting Officer & Director
    Comp: $180k
  • Dr. Mark C. Glassy Ph.D. (Age 72)
    Founder
    Comp: $43k
  • Dr. Navpaul Singh M.D.
    Chief Medical Consultant

Key Competitors

View All Competitors

NBIO Stock Analysis - Frequently Asked Questions

How have NBIO shares performed in 2024?

Nascent Biotech's stock was trading at $0.1729 at the beginning of the year. Since then, NBIO shares have decreased by 46.6% and is now trading at $0.0924.
View the best growth stocks for 2024 here.

Are investors shorting Nascent Biotech?

Nascent Biotech saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 17,900 shares, an increase of 21.8% from the March 15th total of 14,700 shares. Based on an average trading volume of 27,100 shares, the days-to-cover ratio is currently 0.7 days.
View Nascent Biotech's Short Interest.

When is Nascent Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Saturday, June 29th 2024.
View our NBIO earnings forecast.

What other stocks do shareholders of Nascent Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nascent Biotech investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Akero Therapeutics (AKRO), CymaBay Therapeutics (CBAY), Cumberland Pharmaceuticals (CPIX), Entasis Therapeutics (ETTX), Evelo Biosciences (EVLO), Kaleido Biosciences (KLDO).

How do I buy shares of Nascent Biotech?

Shares of NBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NBIO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith